Selling Pudong is a business thriller set inside the wreckage of a failed race to deliver an mRNA COVID-19 vaccine. When the original company collapses, its investors carve out a new venture JunRNA, an Integrated Drug Development Organization meant to salvage value, credibility, and control. To lead the effort, they recruit Delaney Olson, a seasoned biologics manufacturing veteran tasked with turning instability into a functioning company. What follows is a volatile journey of rapid growth and sudden reversals, where scientific progress, investor demands, and political pressure collide. Every gain is fragile. Every decision carries risk. Working against Delaney is Mr. He, the powerful CEO of Tri Lateral Investments, whose influence shapes outcomes behind closed doors. Support turns to resistance, and cooperation gives way to quiet obstruction. The struggle is not just about building a company, but about who ultimately controls it. Set against the backdrop of rising tension between the United States and China, Selling Pudong reveals how geopolitics, capital, and biotech became entangled—and why today’s pro-tariff policies are rooted in years of mistrust and misalignment. This is a story about ambition, power, and the cost of building innovation across a fractured global divide.